The Bankruptcy Court hearing on September 10, 2026, is the next critical catalyst. If the sale is approved, Sangamo will effectively be a shell with no operating assets and only contingent milestone payment rights. The common stock (SGMOQ) is likely to be worthless post-bankruptcy. Monitor for any competing bids or objections at the hearing. The milestone payments are highly speculative and contingent on FDA approval of ST-920, which is still in Phase 1/2.
Price Chart
Executive Summary
Sangamo Therapeutics, already in Chapter 11 bankruptcy, has entered into an asset purchase agreement with PTC Therapeutics to sell its lead gene therapy asset, ST-920 (isaralgagene civaparvovec) for Fabry disease, for $111M cash at closing plus up to $100M in milestone payments. The sale is subject to Bankruptcy Court approval at a hearing scheduled for September 10, 2026. This filing confirms the company's liquidation of its primary remaining asset, with common stock likely to receive no recovery given the bankruptcy process and prior delisting from Nasdaq.
Key Financial Metrics
Key Facts
- Sangamo filed for Chapter 11 bankruptcy on June 23, 2026 (Case No. 26-10989).
- On August 25, 2026, Sangamo entered into an Asset Purchase Agreement with PTC Therapeutics to sell ST-920 (isaralgagene civaparvovec) for Fabry disease.
- Total consideration: $111M cash at closing plus up to $100M in contingent milestone payments ($80M on accelerated FDA approval, $20M on full FDA approval).
- The sale is subject to Bankruptcy Court approval; a hearing is scheduled for September 10, 2026.
- Sangamo's common stock was delisted from Nasdaq on May 5, 2026, and now trades on the OTC under symbol SGMOQ.
- The PTC APA contains no survival of representations and warranties and no indemnification for breach after closing.
- PTC must use commercially reasonable efforts to achieve milestones but has no obligation to conduct additional trials beyond the STAAR studies.
- The agreement can be terminated if closing does not occur by October 15, 2026.
- Sangamo grants PTC a non-exclusive license under certain IP assets for its hemophilia A candidate and proprietary capsids.
- Raymond James is the investment banker for Sangamo, with fees to be paid by Seller.
Financial Impact
Total consideration of $111M cash at closing plus up to $100M in contingent milestone payments. The $111M cash will be used to pay bankruptcy administrative claims, secured creditors, and professional fees; common equity holders are expected to receive no recovery.
Risk Factors
- Bankruptcy Court may not approve the sale or may approve it on different terms.
- A competing bid could emerge at or before the September 10 hearing, potentially altering the deal structure.
- The milestone payments are contingent on FDA approval of ST-920, which is unproven and may never occur.
- Common equity holders are expected to receive no distribution in the Chapter 11 case.
- The PTC APA can be terminated if closing does not occur by October 15, 2026, or if a competing transaction is consummated.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-374328 |
| Document: 0001193125-26-374328-index.html | 0001193125-26-374328 |
| Document: 0001193125-26-374328.txt | 0001193125-26-374328 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | 8-K | $0.1100 $0.1200 | ▼ −9.09% | ▼ −9.52% | $0.1200 (−9.09%) |
Oct 6, 2026 19d ago | 25-NSE | $0.1400 $0.1400 | · 0.00% | ▼ −0.98% | $0.1200 (+14.29%) |
Aug 28, 2026 8w ago | 8-K | $0.1600 $0.1600 | · 0.00% | ▼ −0.14% | $0.1200 (+25.00%) |
Aug 12, 2026 10w ago | 8-K | $0.1700 $0.1602 | ▼ −5.76% | ▼ −3.80% | $0.1200 (−29.41%) |
Aug 12, 2026 10w ago | 8-K | $0.1700 $0.1602 | ▲ +5.76% | ▲ +3.80% | $0.1200 (+29.41%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers